China SXT Pharmaceuticals (SXTC) Receivables - Other (2018 - 2025)
China SXT Pharmaceuticals (SXTC) has 8 years of Receivables - Other data on record, last reported at $108281.0 in Q1 2025.
- For Q1 2025, Receivables - Other rose 29.47% year-over-year to $108281.0; the TTM value through Mar 2025 reached $108281.0, up 29.47%, while the annual FY2025 figure was $108281.0, 29.47% up from the prior year.
- Receivables - Other reached $108281.0 in Q1 2025 per SXTC's latest filing, up from $83634.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $288936.0 in Q1 2022 and bottomed at $83634.0 in Q1 2024.
- Average Receivables - Other over 5 years is $178372.6, with a median of $180370.0 recorded in 2021.
- Peak YoY movement for Receivables - Other: soared 60.19% in 2022, then tumbled 63.74% in 2024.
- A 5-year view of Receivables - Other shows it stood at $180370.0 in 2021, then skyrocketed by 60.19% to $288936.0 in 2022, then decreased by 20.18% to $230642.0 in 2023, then crashed by 63.74% to $83634.0 in 2024, then rose by 29.47% to $108281.0 in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $108281.0 in Q1 2025, $83634.0 in Q1 2024, and $230642.0 in Q1 2023.